FORT LAUDERDALE, Fla., Dec. 8 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc. announced good commercial and clinical response to international clinical results shown at RSNA 2005, the 91st Scientific Assembly and Annual Meeting of the Radiological Society of North America. RSNA is IDSI’s major event of the year, a forum in which to present clinical results, work-in-progress, and international commercial results to more than 60,000 attendees.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )
IDSI featured results from its exclusive CT Laser Mammography (CTLM(R)) scanner and highlighted its leadership in laser optical mammography technology by exhibiting select clinical cases from the more than 6,000 studies that have been completed worldwide.
“We presented cases from many of our luminary and partner sites, which showed CTLM results in the context of complete cases worked up with mammography, ultrasound, breast MRI, and biopsy results,” explained Eric Milne, MD, FRCR, FRCP, IDSI Director of Clinical Research. “The comparisons were particularly useful to illustrate the adjunctive value of imaging the angiogenesis processes with passive CT laser technologies.”
Tim Hansen, IDSI Chief Executive Officer, stated, “We were extremely pleased to have garnered such great interest in our revolutionary new modality and our approach to detecting and managing breast cancer. Our users presented compelling clinical results, our international distributors brought in attentive and interested prospects, and we received serious attention from university-level radiologists who are beginning to understand the key role CTLM may play in multimodality breast cancer case management.”
Commented Dr. Milne, “The acceptance of our non-invasive optical method of detecting angiogenesis in breast cancer, which we have been developing and promulgating for close to ten years, has been confirmed at this year’s RSNA meeting by the virtual ‘explosion’ in technical developments of MRI of the breast, designed to image angiogenesis, and in the many papers presented on angiogenesis in breast cancer.”
IDSI also received international media attention, providing interviews to German and American publications as well as Australian television.
The CTLM(R) system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000- 13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM(R) system to be used as an adjunct to mammography.
Please visit Imaging Diagnostic Systems’ website at: http://www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc. is included in the Company’s filing with the Securities Exchange Commission.
Investor Relations: Rick Lutz 404-261-1196 lcgroup@mindspring.com
Photo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comImaging Diagnostic Systems, Inc.
CONTACT: Investor Relations, Rick Lutz, +1-404-261-1196, orlcgroup@mindspring.com, for Imaging Diagnostic Systems, Inc.
Web site: http://www.imds.com/